Hyperinflammatory Syndromes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA vaccination in Individuals With Underlying Immune Dysregulation

• Type of Material: Article
• Authors: Joseph M Rocco, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Christina Mallarino-Haeger, Emory University; Attiya H Randolph, George Washington Univ Med & Hlth Sci; Susan Ray, Emory University; Marcos Schechter, Emory University; Christa S Zerbe, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Steven M Holland, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Irini Sereti, National Institute of Allergy and Infectious Diseases, NIH, Bethesda
• Language: English
• Date: 2022-01-29
• Publisher: OXFORD UNIV PRESS INC
• Publication Version: Final Published Version
• Copyright Statement: Published by Oxford University Press for the Infectious Diseases Society of America 2021.
• Final Published Version (URL): http://dx.doi.org/10.1093/cid/ciab1024
• Title of Journal or Parent Work: CLINICAL INFECTIOUS DISEASES
• Volume: 75
• Issue: 1
• Start Page: E912
• End Page: E915
• Grant/Funding Information: This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
• Keywords: Vaccination; Life Sciences & Biomedicine; Inflammation; COVID-19; Immunology; Microbiology; Science & Technology; Infectious Diseases; CLINICAL-FEATURES; hemophagocytic lymphohistiocytosis
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

The development of effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines has been a significant accomplishment. Adverse events are extremely rare, but continued surveillance is important, especially in at-risk populations. In 5 patients with preexisting immune dysregulation, hyperinflammatory syndromes, including hemophagocytic lymphohistiocytosis, developed after SARS-CoV-2 mRNA vaccination. Early recognition of this rare condition is essential.